NCT00244855 · OUTCOME

Progression-free Survival

Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma · Source last updated 2017-05-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Kaplan-Meier estimated % of patients
Interval / dispersion: 95% Confidence Interval
Time frame: At 3 and 6 months after enrollment

What was measured

Survival without measurable progression of lymphoma estimated according to the Kaplan-Meier method

Groups in this outcome

Previous Treatment

Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies

No Previous Treatment

Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Previous Treatment	7
No Previous Treatment	25

Reported measurements

At 3 months after enrollment

Values in Kaplan-Meier estimated % of patients · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Previous Treatment	92	Not reported	81	100	Not reported
No Previous Treatment	71	Not reported	45	100	Not reported

At 6 months after enrollment

Values in Kaplan-Meier estimated % of patients · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Previous Treatment	83	Not reported	70	100	Not reported
No Previous Treatment	71	Not reported	45	100	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
81
upper Limit
100
value
92
group Id
OG001
lower Limit
45
upper Limit
100
value
71
title
At 3 months after enrollment
categories
measurements
group Id
OG000
lower Limit
70
upper Limit
100
value
83
group Id
OG001
lower Limit
45
upper Limit
100
value
71
title
At 6 months after enrollment

denoms

counts
group Id
OG000
value
7
group Id
OG001
value
25
units
Participants

description

Survival without measurable progression of lymphoma estimated according to the Kaplan-Meier method

dispersion Type

95% Confidence Interval

groups

description
Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies
id
OG000
title
Previous Treatment
description
Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies
id
OG001
title
No Previous Treatment

param Type

NUMBER

reporting Status

POSTED

time Frame

At 3 and 6 months after enrollment

title

Progression-free Survival

type

PRIMARY

unit Of Measure

Kaplan-Meier estimated % of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice